Angelo M. De Marzo
YOU?
Author Swipe
View article: A transition zone enriched <i>WIF1</i> ⁺ basal cell subtype is associated with benign prostatic hyperplasia
A transition zone enriched <i>WIF1</i> ⁺ basal cell subtype is associated with benign prostatic hyperplasia Open
/SUMMARY The cellular composition and disease susceptibilities of the distinct zones of the human prostate remain incompletely understood. Through extensive single-cell RNA sequencing (scRNA-seq) of benign regions from prostatectomy specim…
View article: Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer Open
Supraphysiological androgen (SPA) treatment can paradoxically restrict growth of castration-resistant prostate cancer with high androgen receptor (AR) activity, which is the basis for use of Bipolar Androgen Therapy (BAT) for patients with…
View article: International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1
International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1 Open
Working Group 1 at ISUP’s Cancer Precursors meeting (September 2024) evaluated 5 putative precursors of invasive prostate cancer: high-grade prostatic intraepithelial neoplasia (HGPIN), intraductal carcinoma (IDC), atypical intraductal pro…
View article: Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer
Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer Open
A significant subset of well-differentiated prostatic acinar neoplasms with invasive histologic features will not spread outside of the prostate, become symptomatic, or shorten a patient’s life even if the tumor is left untreated. Overdiag…
View article: Cell Type-Specific Effects of miR-21 Loss Attenuate Tumor Progression in MYC-Driven Prostate Cancer
Cell Type-Specific Effects of miR-21 Loss Attenuate Tumor Progression in MYC-Driven Prostate Cancer Open
Aberrant microRNA expression is common in cancer, yet cell-type-specific microRNA activity in the tumor microenvironment (TME) remains poorly understood. Here, we show that germline deletion of miR-21 significantly attenuated the progressi…
View article: Nectin‐4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study
Nectin‐4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study Open
Background The Nectin‐4 directed antibody drug conjugate enfortumab vedotin (EV) has emerged as frontline systemic therapy in combination with immune checkpoint blockade for urothelial carcinoma (UC), capitalizing on the ubiquitous express…
View article: Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer Open
Supraphysiological androgen (SPA) treatment can paradoxically restrict growth of castration-resistant prostate cancer with high androgen receptor (AR) activity, which is the basis for use of Bipolar Androgen Therapy (BAT) for patients with…
View article: Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabeling
Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabeling Open
Background Implications of relabeling Grade Group 1 prostate cancer as noncancer will depend on the recommended active surveillance strategy. Whether relabeling should prompt deintensifying, prostate-specific antigen (PSA)–based active mon…
View article: Supplemental Figure S5 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Supplemental Figure S5 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Supplemental Figure S5. Top differentially expressed genes by expression level and statistical significance.
View article: Supplemental Figure S3 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Supplemental Figure S3 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Supplemental Figure S3. Top differentially activated GO pathways with ADT.
View article: Supplemental Figure S4 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Supplemental Figure S4 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Supplemental Figure S4. GO Activated Immune Response Genes.
View article: Supplemental Figure S1 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Supplemental Figure S1 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Supplemental Figure S1. Sample clustering by RNAseq and top differentially expressed genes by treatment group.
View article: Supplemental Figure S6 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Supplemental Figure S6 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Supplemental Figure S6. Spatial proximity between immune cells and tumor cells.
View article: Data from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Data from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Purpose:Androgen deprivation therapy (ADT) remains the backbone of prostate cancer treatment. Beyond the suppression of testosterone and tumor cell growth, emerging evidence suggests that ADT also modulates the immune tumor microenvironmen…
View article: Supplemental Figure S2 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Supplemental Figure S2 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Supplemental Figure S2. Differential expression of androgen-related genes with or without degarelix.
View article: pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy
pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy Open
Background The transcription factor Signal Transducer and Activator of Transcription 3 (STAT3) plays a role in carcinogenesis and is involved in processes, such as proliferation, differentiation, drug resistance and immunosuppression. STAT…
View article: Detection of Alternative Lengthening of Telomeres via Chromogenic In Situ Hybridization for the Prognostication of PanNETs and Other Neoplasms
Detection of Alternative Lengthening of Telomeres via Chromogenic In Situ Hybridization for the Prognostication of PanNETs and Other Neoplasms Open
Molecular studies have shown alternative lengthening to telomeres (ALT) to be an important prognostic biomarker of shorter relapse-free survival (RFS) for patients with pancreatic neuroendocrine tumors (PanNETs) and other neoplasms. Howeve…
View article: SPOT: spatial proteomics through on-site tissue-protein-labeling
SPOT: spatial proteomics through on-site tissue-protein-labeling Open
Background Spatial proteomics seeks to understand the spatial organization of proteins in tissues or at different subcellular localization in their native environment. However, capturing the spatial organization of proteins is challenging.…
View article: Supplementary Table S1 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer
Supplementary Table S1 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer Open
Supplementary Table S1 shows patient and tumor characteristics from the patients who underwent radical prostatectomies for this study.
View article: Supplementary Figure S3 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer
Supplementary Figure S3 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer Open
Supplementary Figure S3 shows the GSTP1 promoter methylation and its corresponding GSTP1 immunohistochemistry expression for PIA and PIN lesions within an individual patient, and notably the heterogeneity of the PIA lesions.
View article: Supplementary Table S2 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer
Supplementary Table S2 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer Open
Supplementary Table S2 shows the phased methylation of the GSTP1 promoter region across 102 lesions classified by density of methylation.
View article: Supplementary Table S1 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer
Supplementary Table S1 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer Open
Supplementary Table S1 shows patient and tumor characteristics from the patients who underwent radical prostatectomies for this study.
View article: Supplementary Figure S2 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer
Supplementary Figure S2 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer Open
Supplementary Figure S2 shows the methylation rate by allele of the GSTP1 promoter region for partially methylated PIN alleles and demonstrates a hotspot of methylation around transcription factor binding sites and the transcription start …
View article: Supplementary Figure S1 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer
Supplementary Figure S1 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer Open
Supplementary Figure S1 shows the phased methylation by allele of the GSTP1 promoter region classified by density of methylation.
View article: Supplementary Table S2 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer
Supplementary Table S2 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer Open
Supplementary Table S2 shows the phased methylation of the GSTP1 promoter region across 102 lesions classified by density of methylation.
View article: Supplementary Table S3 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer
Supplementary Table S3 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer Open
Supplementary Table S3 shows the phased methylation of the GSTP1 promoter region across 908 alleles, or clones, classified by density of methylation.
View article: Supplementary Figure S2 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer
Supplementary Figure S2 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer Open
Supplementary Figure S2 shows the methylation rate by allele of the GSTP1 promoter region for partially methylated PIN alleles and demonstrates a hotspot of methylation around transcription factor binding sites and the transcription start …
View article: Supplementary Figure S1 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer
Supplementary Figure S1 from Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer Open
Supplementary Figure S1 shows the phased methylation by allele of the GSTP1 promoter region classified by density of methylation.